Table 1.
Demographic and clinical characteristics of the study groups
| Discovery Cohort | Replication Cohort | ||||
|---|---|---|---|---|---|
| Variables | Cases (n = 104) | Controls (n = 485) | Cases (n = 32) | Controls (n = 261) | |
| Age, years (mean ±SD) | 36.62±14.39 | 35.88±14.23 | 36.53±16.88 | 30.29±15.14 | |
| Sex (%) | Female | 50 (48.1) | 232 (47.8) | 13 (40.6) | 137 (52.5) |
| Male | 54 (51.9) | 253 (52.2) | 19 (59.4) | 124 (47.5) | |
| Smoking n (%) | 40 (38.5) | 187 (38.1) | 15 (46.9) | 83 (31.8) | |
| GI dysplasia/ Cancer n (%) | 5 (4.8) | 34 (7) | 3 (9.4) | 14 (5.4) | |
| Calcineurin inhibitor n (%) | 2 (1.9) | 6 (1.2) | - | 3 (1.1) | |
| * Antibiotics n (%) | 26 (25) | 225 (46.4) | 13 (40.6) | 115 (45.1) | |
| * Methotrexate n (%) | 9 (8.7) | 88 (18.1) | 5 (16.1) | 65 (25) | |
| * Azathioprine n (%) | 46 (44.2) | 276 (56.9) | 11 (34.4) | 128 (49.8) | |
| Aminosalicylates n (%) | 33 (32) | 140 (29.2) | 11 (35.5) | 60 (23.6) | |
| Anti-TNFα therapy | |||||
| Infliximab n (%) | 66 (64.1) | 328 (67.9) | 14 (43.8) | 154 (59) | |
| Adalimumab n (%) | 29 (28.2) | 146 (30.2) | 17 (53.1) | 98 (37.5) | |
| Certolizumab n (%) | 9 (8.6) | 11 (2.3) | 1 (3.1) | 9 (3.4) | |
| IBD type | |||||
| Crohn’s Disease n (%) | 73 (70.2) | 387 (80) | 28 (87.5) | 255 (98) | |
| Ulcerative Colitis n (%) | 28 (26.9) | 85 (17.5) | - | - | |
| Indeterminate Colitis n (%) | 3 (2.8) | 13 (2.6) | 4 (12.5) | 6 (2.3) | |
*
p <0.05, statistically significant in the discovery cohort